15-12-2011: BioInvent International AB announced that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density. The results were presented at the American Society of Hematology (ASH) Annual Meeting.
The study was conducted by researchers at the University of Utah, Salt Lake City, USA under the direction of Professor Guido Tricot. Compared to untreated controls, BI-505 treated animals showed a significant reduction (p-value <0.01) of tumour burden induced by primary human multiple myeloma cells as measured by human IgG levels. The active control, bortezomid (Velcade®, Takeda/ Millennium) also showed significant effect (p-value <0.01) over the placebo control.
Svein Mathisen, President and CEO of BioInvent, said: “Current pharmaceutical regimes in multiple myeloma are associated with severe negative side effects. It is our belief that an antibody-based regime would make a meaningful difference in this respect. These preclinical data on the anti-cancer activity of BI-505, well in line with one of the leading cytotoxics, take us one step in that direction.”
A second outcome investigated in the study was bone resorption. This is very important to multiple myeloma patients because, as the disease progresses, lysis, or breakdown, of bone causes increasing pain. This lysis is caused by the shift in balance in favour of osteoclasts, the bone cells in charge of skeletal breakdown, over osteoblasts, bone cells promoting build-up. The study demonstrated that both BI-505 and Velcade had a favourable effect on bone mineral density.
In a previous animal model BioInvent has also shown BI-505 to prolong survival compared to Velcade.
ThromboGenics NV and co-development partner BioInvent International announced the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto®; Bayer), an oral anticoagulant. The study showed that the incidence of venous thromboembolism (VTE) ... more
BioInvent International AB announced that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone density. The results were presented at the American Society of Hematology (ASH) Annual Meeting. ... more
BioInvent International AB and co-development partner ThromboGenics NV announced that their partner Roche has dosed the first patient in a phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334). The trial is in patients with glioblastoma multiforme, the most common and ... more
BioInvent develops antibody drugs
BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases. more